Zhong Guo Jing Ji Wang·2025-10-15 06:24Core Insights - The company, Oriental Bio, reported a decline in revenue and net profit for the first half of 2025, indicating ongoing financial challenges [1] - In 2024, the company experienced a slight increase in revenue but a significant increase in net losses compared to the previous year [2] Financial Performance - In the first half of 2025, Oriental Bio achieved operating revenue of 403 million yuan, a year-on-year decrease of 3.62% [1] - The net profit attributable to shareholders was -163 million yuan, compared to -152 million yuan in the same period last year [1] - The net profit after deducting non-recurring gains and losses was -184 million yuan, an improvement from -207 million yuan year-on-year [1] - The net cash flow from operating activities was -123 million yuan, an improvement from -332 million yuan in the previous year [1] 2024 Financial Overview - In 2024, the company reported operating revenue of 828 million yuan, a year-on-year increase of 0.95% [2][3] - The net profit attributable to shareholders was -529 million yuan, a significant increase in losses compared to -398 million yuan in the previous year, reflecting a 33.06% decline [2][3] - The net profit after deducting non-recurring gains and losses was -571 million yuan, also a significant increase in losses compared to -431 million yuan in the previous year, reflecting a 32.60% decline [2][3] - The net cash flow from operating activities was -348 million yuan, an improvement from -1.646 billion yuan in the previous year [2] Fundraising and Use of Proceeds - Oriental Bio raised a total of 637.5 million yuan from its issuance, with a net amount of 550.8 million yuan after expenses [4] - The final net amount raised was 10.82 million yuan less than originally planned [4] - The funds are intended for projects including the production of rapid diagnostic products, technology research and development, marketing network construction, and working capital [4][5]